Deerfield Mgmt Reports Significant Stake in CalciMedica (CALC)
Ticker: CALC · Form: SC 13G · Filed: Feb 1, 2024 · CIK: 1534133
| Field | Detail |
|---|---|
| Company | Calcimedica, INC. (CALC) |
| Form Type | SC 13G |
| Filed Date | Feb 1, 2024 |
| Risk Level | low |
| Pages | 8 |
| Reading Time | 10 min |
| Sentiment | bullish |
Complexity: simple
Sentiment: bullish
Topics: institutional-ownership, SC-13G, biotech, investor-confidence
Related Tickers: CALC
TL;DR
**Deerfield Mgmt just disclosed a big stake in CalciMedica, signaling institutional confidence.**
AI Summary
Deerfield Mgmt, L.P., a New York-based investment firm, reported on February 1, 2024, that it holds a significant stake in CalciMedica, Inc. (NASDAQ: CALC). This SC 13G filing, triggered by an event on January 23, 2024, indicates that Deerfield Mgmt, L.P. is part of a group that collectively owns a substantial portion of CalciMedica's common stock. This matters to investors because a large institutional holder like Deerfield Mgmt, L.P. taking a significant position can signal confidence in the company's future, potentially influencing other investors and the stock price.
Why It Matters
This filing reveals a major institutional investor's substantial ownership in CalciMedica, which can be seen as a vote of confidence and may attract further investor interest.
Risk Assessment
Risk Level: low — This filing indicates a large institutional investment, generally seen as a positive signal rather than a risk.
Analyst Insight
A smart investor would note this institutional investment as a potential positive indicator and research CalciMedica's recent developments and financial health to understand the basis of Deerfield Mgmt's confidence.
Key Players & Entities
- Deerfield Management Company, L.P. (company) — group member reporting ownership
- Deerfield Mgmt, L.P. (company) — reporting person and group member
- Deerfield Partners, L.P. (company) — group member reporting ownership
- CalciMedica, Inc. (company) — the issuer whose securities are being reported
- Flynn James E (person) — filer of the SC 13G
FAQ
What is the CUSIP number for CalciMedica, Inc.'s Common Stock mentioned in this filing?
The CUSIP number for CalciMedica, Inc.'s Common Stock is 38942Q202, as stated on page 1 of the filing.
What was the 'Date of Event Which Requires Filing of this Statement' for this SC 13G?
The 'Date of Event Which Requires Filing of this Statement' was January 23, 2024, as indicated on page 1 of the filing.
Which rule under the Securities Exchange Act of 1934 is this Schedule 13G filed pursuant to?
This Schedule 13G is filed pursuant to Rule 13d-1(c), as marked by the checkbox on page 1 of the filing.
Who are the specific 'GROUP MEMBERS' listed in this filing?
The specific 'GROUP MEMBERS' listed are DEERFIELD MANAGEMENT COMPANY, L.P., DEERFIELD MGMT, L.P., and DEERFIELD PARTNERS, L.P., as detailed in the header information of the filing.
What is the business address of CalciMedica, Inc. as per this filing?
CalciMedica, Inc.'s business address is 505 Coast Boulevard South, Suite 307, La Jolla, CA 92037, according to the 'BUSINESS ADDRESS' section of the filing.
Filing Stats: 2,538 words · 10 min read · ~8 pages · Grade level 7.8 · Accepted 2024-02-01 17:29:56
Filing Documents
- e619220_sc13g-calcimedica.htm (SC 13G) — 102KB
- 0001193805-24-000118.txt ( ) — 104KB
(a)
Item 1(a). Name of Issuer: CalciMedica Inc.
(b)
Item 1(b). Address of Issuer's Principal Executive Offices: 505 Coast Boulevard South, Suite 307 La Jolla, CA 92037
(a)
Item 2(a). Name of Person Filing: James E. Flynn, Deerfield Mgmt, L.P., Deerfield Management Company, L.P. and Deerfield Partners, L.P.
(b)
Item 2(b). Address of Principal Business Office, or if None, Residence: James E. Flynn, Deerfield Mgmt, L.P., Deerfield Management Company, L.P. and Deerfield Partners, L.P., 345 Park Avenue South, 12th Floor, New York, NY 10010
(c)
Item 2(c). Citizenship: Deerfield Mgmt, L.P., Deerfield Management Company, L.P. and Deerfield Partners, L.P. - Delaware limited partnerships; James E. Flynn – United States citizen
(d)
Item 2(d). Title of Class of Securities: Common Stock
(e)
Item 2(e). CUSIP Number: 38942Q202 Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a: (a) Broker or dealer registered under Section 15 of the Exchange Act. (b) Bank as defined in Section 3(a)(6) of the Exchange Act. (c) Insurance company as defined in Section 3(a)(19) of the Exchange Act. (d) Investment company registered under Section 8 of the Investment Company Act. (e) An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); (f) An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); (g) A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G); (h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act; (i) A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act; CUSIP No. 38942Q202 13G Page 7 of 9 (j) A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J); (k) Group, in accordance with Rule 13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: ___________________________________________ Item 4. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned**: Deerfield Mgmt, L.P. - 2,613,012 shares Deerfield Management Company, L.P. - 2,613,012 shares Deerfield Partners, L.P. - 2,613,012 shares James E. Flynn – 2,613,012 shares (b) Percent of class**: Deerfield Mgmt, L.P. – 9.99% Deerfield Management Company, L.P. – 9.99% Deerfield Partners, L.P. - 9.99% James E. Flynn – 9.99% (c) Number of shares as to which such person has**: (i) Sole power to vote or to direct the vote: All Reporting Persons - 0 (ii) Shar